CollPlant Biotechnologies Ltd financial data

Symbol
CLGN on Nasdaq
Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Location
4 Oppenheimer St., 11 Th Floor, Rehovot, Israel
State of incorporation
Israel
Fiscal year end
December 31
Former names
CollPlant Holdings Ltd. (to 6/6/2019)
Latest financial report
6-K - Q2 2024 - Aug 20, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11.5M shares +2.38%
Common Stock, Shares, Outstanding 11.5M shares +0.43%
Common Stock, Value, Issued 4.98M USD +0.4%
Weighted Average Number of Shares Outstanding, Basic 11.5M shares +0.75%
Weighted Average Number of Shares Outstanding, Diluted 11.5M shares -2.74%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 249K USD -97.6%
Cost of Revenue 536K USD -12.8%
Research and Development Expense 2.7M USD +4.78%
General and Administrative Expense 1.42M USD +7.89%
Operating Income (Loss) -4.41M USD -178%
Nonoperating Income (Expense) 196K USD +131%
Net Income (Loss) Attributable to Parent -4.21M USD -173%
Earnings Per Share, Basic -0.37 USD/shares -173%
Earnings Per Share, Diluted -0.37 USD/shares -176%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 18.9M USD -15.1%
Accounts Receivable, after Allowance for Credit Loss, Current 250K USD
Inventory, Net 439K USD -71.7%
Assets, Current 20.3M USD -41.7%
Property, Plant and Equipment, Net 2.56M USD -12.6%
Operating Lease, Right-of-Use Asset 3.4M USD +2.13%
Intangible Assets, Net (Excluding Goodwill) 159K USD -26.4%
Assets 26.6M USD -36.1%
Liabilities, Current 3.24M USD +16.5%
Operating Lease, Liability, Noncurrent 2.6M USD -5.53%
Liabilities 5.84M USD +5.55%
Accumulated Other Comprehensive Income (Loss), Net of Tax -969K USD
Retained Earnings (Accumulated Deficit) -105M USD -19.9%
Stockholders' Equity Attributable to Parent 20.7M USD -42.5%
Liabilities and Equity 26.6M USD -36.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 30M shares 0%
Common Stock, Shares, Issued 11.5M shares +0.43%
Common Stock, Par or Stated Value Per Share 1.5 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18.9M USD -15.4%
Deferred Tax Assets, Valuation Allowance 18.5M USD -17.5%
Deferred Tax Assets, Gross 19.2M USD -16.6%
Operating Lease, Liability 3.16M USD +8.52%
Lessee, Operating Lease, Liability, to be Paid 3.82M USD
Property, Plant and Equipment, Gross 8.84M USD +10.3%
Operating Lease, Liability, Current 789K USD +31.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 768K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 824K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 663K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 664K USD
Deferred Tax Assets, Operating Loss Carryforwards 15.5M USD -22.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 636K USD
Additional Paid in Capital 120M USD
Deferred Tax Assets, Net of Valuation Allowance 22.5M USD +42%
Share-based Payment Arrangement, Expense 490K USD +45%